Overview:
Cluster Headache Market
Cluster headache is a group of severe, painful headaches
that occur over a short period of time, usually in a day or a few hours. The
pain is always on one side of the face and is usually not throbbing like
migraines. They happen more often in men than women and they can occur at any
age, but are most common in people 20s through middle age. They tend to run in
families and may be triggered by smoking or drinking alcohol. It is also
suspected that there is a connection to a part of the brain called the
hypothalamus. The most effective medicine is sumatriptan, which works quickly
and effectively to stop a cluster headache. Rising
product approvals are estimated to augment the growth of the global Cluster Headache Market during
the forecast period. Other medicines, such as prednisone and lithium carbonate,
can also be used to help reduce the severity or duration of a headache. They
may also be used as preventive medicines to stop cluster headaches from
occurring.
Market
Dynamics:
For instance,
Pfizer Inc. declared that their ZAVZPRET™ has been approved by the US FDA in
March 2023. This is the first and only calcitonin gene-related peptide (CGRP)
receptor antagonist nasal spray that is used for treating acute migraine in
adults. Moreover, increasing non-favorable
reimbursement scenarios are anticipated to restrain the growth of the global Cluster
Headache Market during the forecast period.
Impact
of COVID-19:
The pandemic was first reported in 2019 in China, and it
affected the entire nation. This outbreak had a severe impact on the growth of several markets globally. The pandemic also affected other nations such as
Spain, Italy, France, India, the US, and many more. These nations implemented
several strict restrictions for preventing the transmission of the virus. These
restrictions also affected several other markets, by halting their
manufacturing activities. The pandemic had a huge impact on the healthcare
sector. People were forced to stay at home owing to social distancing
restrictions. This hampered the growth of the global Cluster
Headache Market,
as people could not visit clinics or continue their ongoing treatments.
However, the market is expected to wines s high growth in the post-pandemic
era.
Key Takeaways:
The
global Cluster Headache Market is
expected to witness robust growth, exhibiting a CAGR of 6.4 % over the forecast period, due to increasing agreements
among key players.
For instance, AstraZeneca announced the agreement
for global rights of Zomig (zolmitriptan) outside Japan in June 2021.
North America is anticipated to
witness robust growth in the global market during the forecast
period, due to growing healthcare infrastructure
and rising prevalence of migraine.
Key
players active in the global Cluster
Headache Market
are Mylan N.V., Bayer AG,
WOCKHARDT, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Novartis AG,
Eli Lilly and Company, AstraZeneca, Lupin Pharmaceuticals, Inc., Pfizer Inc.,
GlaxoSmithKline plc, Sanofi, Takeda Pharmaceutical Company Limited, Johnson
& Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc.,
Sun Pharmaceutical Industries Ltd., Allergan, and Amgen Inc.
Did you know that cluster headaches are often referred to as "suicide headaches" due to their intense and excruciating pain, which can drive some individuals to contemplate self-harm as a means of escape?
Posts
0 Comments